SLNO Stock Plunges 27% on Safety Concerns: Class Action Lawsuit Targets Soleno Therapeutics

Soleno Therapeutics Inc. ($SLNO) faces a securities class action lawsuit alleging the company concealed critical safety risks and overstated commercial performance metrics for VYKAT™ XR, its flagship treatment for Prader-Willi syndrome. The allegations emerged after an activist short seller report in August 2025 and disappointing third-quarter financial results in November 2025 exposed significant gaps between the company's public statements and market realities, triggering a dramatic 27% single-day stock decline. The lawsuit, announced by litigation firm Hagens Berman, comes as investors who suffered losses during the March 26 to November 4, 2025 period rush to meet the May 5, 2026 deadline to petition for lead plaintiff status.

The Allegations and Triggering Events

Soleno Therapeutics stands accused of systematically misleading investors about the safety profile and commercial viability of VYKAT™ XR, an oral medication designed to address hyperphagia—severe appetite dysregulation—in patients with Prader-Willi syndrome, a rare genetic disorder affecting approximately 10,000 to 15,000 individuals in the United States.

The lawsuit's foundation rests on two catalyzing events that exposed alleged misrepresentations:

• August 2025 Short Seller Report: An activist short seller published research questioning the company's safety disclosures and challenging the credibility of commercial projections, triggering immediate investor skepticism
• November 2025 Q3 Results: Official financial disclosures revealed substantially lower-than-anticipated patient adoption rates and safety concerns that contradicted prior guidance and investor presentations

The combination of external scrutiny and official confirmation of weaker-than-expected commercial metrics created a credibility crisis. Following the November results announcement, $SLNO experienced a catastrophic 27% single-day decline, erasing billions in market capitalization and devastating shareholders who had invested based on the company's prior representations.

According to Hagens Berman, the company allegedly:

• Concealed known safety risks associated with VYKAT™ XR from regulatory filings and investor communications
• Inflated commercial adoption metrics and revenue guidance
• Failed to disclose competitive pressures and market penetration challenges
• Misrepresented the drug's market potential and physician uptake rates

Market Context and Industry Significance

The $SLNO litigation reflects broader vulnerabilities in the rare disease pharmaceutical sector, where companies often operate with smaller patient populations, limited clinical validation datasets, and heightened information asymmetries between management and investors.

Soleno Therapeutics had positioned itself as a specialist in rare metabolic and neurological disorders, with VYKAT™ XR representing its lead revenue-generating asset. For a company of SLNO's market capitalization and revenue stage, a single flagship product carries disproportionate significance—product delays, safety issues, or adoption shortfalls can rapidly destroy shareholder value.

The Prader-Willi syndrome market represents a compelling but narrow therapeutic opportunity:

• Patient Population: Approximately 10,000-15,000 diagnosed cases in the U.S., with significant unmet medical needs
• Treatment Landscape: Limited FDA-approved therapeutic options for hyperphagia, creating potential differentiation for successful entrants
• Reimbursement Environment: Rare disease treatments often benefit from accelerated approval pathways and orphan drug designation, but commercialization remains challenging due to small patient numbers
• Competitive Dynamics: Specialty pharma companies and larger diversified players are increasingly targeting rare genetic disorders with viable profit margins

The August 2025 short seller catalyst highlights how activist research—while sometimes sensationalized—can expose legitimate disclosure gaps that institutional investors, research analysts, and regulators may have initially overlooked. This dynamic has intensified post-2020 as activist short sellers employ sophisticated data analytics, supply chain intelligence, and regulatory filing analysis to identify potential misstatements.

Investor Implications and Legal Timeline

The lawsuit carries significant consequences for multiple stakeholder groups:

For Affected Shareholders: Investors who purchased $SLNO shares between March 26, 2025 and November 4, 2025—the alleged period of fraudulent misrepresentation—are eligible to pursue damages through the class action mechanism. The May 5, 2026 deadline to petition for lead plaintiff status is critical; lead plaintiffs receive enhanced settlement negotiations and oversight authority.

Lead Plaintiff Requirements: To qualify as lead plaintiff, investors must typically demonstrate:

• Largest financial losses among class members
• Trading activity during the class period
• Willingness to serve as representative and bear associated burdens

Potential Settlement Range: Securities class actions in the biopharmaceutical sector typically settle for 5-20% of shareholder losses, though outcome variability is substantial depending on evidence quality, regulatory findings, and defendant financial resources.

Regulatory Implications: The SEC and FDA may independently investigate whether Soleno Therapeutics violated disclosure obligations under Regulation FD (Fair Disclosure) or made material misstatements in regulatory filings. Such investigations could result in:

• Company-imposed trading suspensions
• Officer-and-director liability findings
• Restrictions on future capital raises
• Potential criminal referrals for executives

Broader Market Considerations: The $SLNO case reinforces investor scrutiny toward:

• Small-cap and micro-cap pharmaceutical companies with concentrated revenue streams
• Management guidance credibility, particularly for companies transitioning from development to commercialization phases
• Clinical trial data quality and post-market safety monitoring disclosures
• Conflict-of-interest arrangements between company insiders and clinical advisory boards

Forward Outlook

As Soleno Therapeutics navigates litigation, regulatory scrutiny, and severe reputational damage, the company faces existential challenges. The 27% single-day stock collapse reflects investor loss of confidence that may be difficult to restore even with operational improvements. Whether the company can stabilize VYKAT™ XR commercialization, maintain regulatory approvals, and survive prolonged litigation remains uncertain.

For the broader investment community, the $SLNO case exemplifies how specialized knowledge, rigorous due diligence, and healthy skepticism of management guidance remain essential—particularly in capital-constrained sectors where single-product dependencies create binary investment outcomes. Investors holding rare disease pharmaceutical equities should reassess disclosure quality, competitive moats, and commercialization progress with heightened scrutiny.

The May 5, 2026 lead plaintiff deadline represents a critical juncture for affected shareholders to formalize their legal claims and participate in what could become a substantial securities recovery litigation.